Digest Réseau Comment ça marche
Réseau
/
Sociétés
Al
Non vérifié

Alzheon, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéScience

13 communiqués de presse

Voir tous les communiqués de presse
02/12/2025
Science
Finance
Médecine - Divers
Associations/Professionnels
Biotechnologie
Santé Publique
Industrie pharmaceutique
Santé
Industrie
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
19/11/2025
Événements
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
14/10/2025
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
15/07/2025
Santé
Santé Publique
Industrie pharmaceutique
Biotechnologie
Web et Réseaux Sociaux
Événements
Industrie
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
10/04/2025
Événements
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
18/03/2025
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Hygiène alimentaire
Médecine - Divers
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
25/02/2025
Science
Biotechnologie
Industrie pharmaceutique
Santé
Hygiène alimentaire
Médecine - Divers
Événements
Industrie
Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
07/01/2025
Marché du travail
Événements
Industrie
Psychiatrie
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
18/09/2024
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
New Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
23/07/2024
Psychiatrie
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Événements
Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0